How to Actually Read a "Side Effects" Section

"No adverse events reported" can mean two completely different things: a phase 3 trial with thousands of patients found nothing, or three people took something once and nobody got sick. Both show up as a clean-looking safety section. Only one of them tells you much.

Three Tiers of Evidence, Not One

Across the compounds we track, side-effect data falls into roughly three buckets, and the gap between them matters more than anything else on the page:

Regulator-reviewed drugs have real population-level data — thousands of patients, defined incidence rates, known interactions. [Tirzepatide](/compound/tirzepatide)'s GI event rates and discontinuation percentages by dose, or [Sildenafil](/compound/sildenafil-viagra-25mg)'s nitrate interaction warning, are this tier: specific, sourced, and backed by trials designed to catch rare events.

Research peptides with thin human data sit in the middle. [BPC-157](/compound/bpc-157) has exactly three small, uncontrolled human pilot studies — all reporting zero adverse events, none randomized or placebo-controlled. A 2025 review calls it "investigational" pending larger trials. Zero adverse events in three people is a real data point. It is not the same statistical confidence as zero adverse events in three thousand.

Compounds with no human safety data at all are the third tier, and it's a bigger bucket than people expect. [TB-500](/compound/tb-500)'s page states it plainly: no human safety data exists for the TB-500 fragment itself, at any dose, via any route. That's not a red flag by itself — it's an honest gap. But it means "side effects: none reported" here is really "side effects: never studied," and those aren't the same sentence.

The Absence of a Listed Side Effect Isn't Proof of Safety

This is the mistake worth avoiding: reading a short or empty side-effects section as reassurance. Sometimes it's actually the more concerning read. [ACE-031](/compound/ace-031) is a clear example — a promising muscle-mass trial in a pediatric population was stopped early after an epistaxis/telangiectasia (nosebleed and visible blood vessel) signal emerged. That's a defining safety finding for the compound, not a footnote, and it only shows up if you look past a one-line summary.

Patterns Worth Recognizing Across Compound Families

A few side-effect patterns repeat across entire categories, and knowing the pattern helps you read a new compound faster:

• GLP-1/GIP-class compounds consistently show GI events (nausea, vomiting, diarrhea) as the dominant adverse-event category, usually dose-related and concentrated during dose escalation.
• GH secretagogues show a desensitization pattern. [Hexarelin](/compound/hexarelin)'s page documents this clearly: repeated daily dosing progressively blunts the GH response within 1–2 weeks, with receptor sensitivity only recovering after roughly 4 weeks off — a real pharmacological limitation, not a rare edge case.
• GHRP-class compounds carry appetite and cortisol effects as a near-defining feature rather than an incidental side effect, more pronounced in some (GHRP-6) than others (GHRP-2, ipamorelin) that act through the same receptor.
• SARMs show dose-dependent hormone suppression. [LGD-4033](/compound/lgd-4033)'s trial data shows suppressed testosterone and SHBG at the tested dose — worth noting the same trial also found levels returned to baseline after stopping, which is a different claim from "no effect at all."

What to Actually Do With This

Before treating a side-effects section as settled, check three things: how many people was this actually observed in, was it a controlled trial or an uncontrolled pilot, and is the number for the exact compound and route you're looking at or for a related-but-different form of it. Every compound page on this site is written to keep that distinction visible rather than collapsing it into a flat bullet list — that's deliberate, and it's the reason two compounds can both say "well tolerated" and mean very different things.